Utmos Drug Interactions

Drugs Affecting Hepatic Microsomal Enzymes: Inhibitors or inducers of cytochrome P-450 (CYP) isoenzyme 3A4; potential pharmacokinetic interaction.
Potential pharmacokinetic interaction (increased peak plasma concentrations and area under the concentration-time curve [AUC] of pioglitazone) with inhibitors of CYP3A4 (e.g. ketoconazole). Pharmacokinetic interaction unlikely with ranitidine, a relatively weak CYP3A4 inhibitor.
Pioglitazone is a weak inducer of CYP3A4. Potential pharmacokinetic interaction (reduction in peak plasma concentration and AUC) with CYP3A4 substrates (e.g. atorvastatin, midazolam, ethinyl estradiol, nifedipine ER).
Potential pharmacokinetic interaction with estrogen-progestin combination contraceptives (small decrease in peak plasma estrogen concentration and AUC): clinical importance unknown.
Pharmacokinetic interaction unlikely with CYP2C9 substrates (e.g. warfarin).
Pharmacokinetic interaction unlikely with theophylline, a CYP1A2 substrate.
Antidiabetic Agents: Pharmacokinetic interaction with metformin or glipizide unlikely.
Digoxin: Pharmacokinetic interaction unlikely.
Fexofenadine Hydrochloride: Pharmacokinetic interaction unlikely.